These results also compare favorably to reported CR/CRi rates (FLT3-ITD: 63%, FLT3-TKD: 76.9%) and median OS (FLT3-ITD: 9.9 months; FLT3-TKD: 19.2 months) in patients with FLT3-mutated AML treated with AZA+VEN [31]. The gene discussed is FLT3; the disease is acute myeloid leukemia.